Certainly, though we tried to design a cost-effective amplicon panel, and it covers most of ATM mutations reported in CLL, only an ATM whole-exome sequencing study will address the precise clinical impact of these gene variants. Here, ATM is linked to B-cell chronic lymphocytic leukemia.